Inovio Pharmaceuticals (NSDQ:INO) shares took a hit this morning on second-quarter results that missed the consensus forecast. INO shares were down more than –11% at $8.53 per share in morning trading today. The Plymouth Meeting, Pa.–based company posted losses of -$82.1 million on sales of $272,824 for the three months ended June 30, 2021, for […]
Business/Financial News
Cigarette maker Philip Morris acquires another inhaled therapeutic company
Philip Morris (NYSE:PM) announced today that it acquired OtiTopic and its late-stage inhalable acetylsalicylic acid (ASA) treatment. Los Angeles-based OtiTopic develops the Asprihale patented dry powder inhalation ASA treatment to treat acute myocardial infarction as a self-administered aerosol. According to a news release, early clinical trials have shown that the product catalyzed peak plasma concentration […]
Insulet slides on mixed-bag Q2 results
Insulet (NSDQ:PODD) posted second-quarter results this week that beat the revenue consensus on Wall Street but missed on earnings estimates. The Acton, Mass.-based company reported losses of -$25 million, or -37¢ per share, on sales of $263.2 million for the three months ended June 30 for a sales growth of 16.31% compared with Q2 2020. Earnings […]
BD handily beats The Street in Q2 — but notes some delta variant effects
BD (NYSE: BDX) posted second-quarter results today that beat the consensus forecast on Wall Street, increasing its full-year guidance. The medtech giant, however, also acknowledged that it’s seeing the COVID-19 delta variant impact elective procedure volumes in some U.S. states. Get the full story on our sister site MassDevice.
Tandem Diabetes Care rises after hours on Street-beating Q2
Tandem Diabetes Care (NSDQ:TNDM) shares ticked up after hours today on second-quarter results that came in well ahead of the consensus forecast. The San Diego-based company posted profits of $4 million on sales of $172.1 million for the three months ended June 30, 2021, for a massive bottom-line gain from losses of -$27.1 million this […]
Eyevensys raises $12M for its gene therapy ocular drug delivery platform
Eyevensys, a developer of gene therapies for ophthalmic diseases, announced today that it raised $12 million in a Series B plus funding round. The funding, led by Korea Investment Partners, also includes existing investors who will join the round and support the accelerated development of Eyevensys’ EYS809 program for treating wet age-related macular degeneration (AMD) […]
FDA clears Abbott’s iPhone app for FreeStyle Libre 2
Abbott (NYSE:ABT) announced today that it received FDA clearance for its FreeStyle Libre 2 iOS application for use with compatible iPhones. The Abbott Park, Ill.-based company designed the new FreeStyle Libre 2 app to enable users to get glucose readings directly on their iPhones without the use of a reader, allowing caregivers to remotely monitor […]
Vaxart stock soars after FDA approves IND application for oral COVID-19 vaccine tablet
Vaxart (NSDQ:VXRT) announced today that the FDA cleared the investigational new drug (IND) application for its oral COVID-19 vaccine. Upon news of the IND application approval for the S-only protein construct-based vaccine candidate, shares of VXRT were up 16.1% at $8.35 in early-morning trading today. South San Francisco-based Vaxart’s S+N oral tablet SARS-CoV-2 vaccine candidate […]
Dexcom beats Street — but remains coy on U.S. G7 launch
Dexcom (NSDQ:DXCM) shares are up more than 13% today — a day after Q2 results that topped the consensus forecast. The San Diego-based continuous glucose monitor developer also announced continued clinical and regulatory progress with its next-gen G7, though the timing of a U.S. G7 release is still an open question. Dexcom posted profits of […]
Tenaya Therapeutics prices $180M IPO for targeted therapies
Tenaya Therapeutics announced that it priced an underwritten, upsized initial public offering of common stock worth $180 million. South San Francisco-based Tenaya develops therapies for rare generic disorders and more prevalent heart conditions through gene therapy, cellular regeneration and precision medicine. The company is actively exploring different routs of administration and different infusion- and injection-based methods […]